ADMA Biologics Stock Performance Shares of NASDAQ ADMA opened at $18.67 on Tuesday. The company has a market capitalization of $4.41 billion, a PE ratio of 66.68 and a beta of 0.60. The company ...

PARIS, March 17, 2025--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing ...

Engineered Exosomes Drug Landscape Report 2025: Market is Dominated by Biologics, with a Focus on Intravenous Administration and Oncology Therapies Research and Markets Fri, Mar 14, 2025, 8:25 AM ...

Peter Marks, the agency’s head of biologics, ultimately overruled reviewers and lower-level officials to approve the treatment for virtually all patients. Most of that debate centered around ...

Agenus Chief Medical Officer Dr. Steven O'Day joined Fierce's Chris Hayden on a recent sponsored episode of The Top Line podcast to discuss the evolving landscape of cancer immunotherapy.

Vincerx Pharma has found a fast fix for the uncertainty over its future. Recently left in limbo by the collapse of its reverse merger, the antibody-drug conjugate (ADC) developer has taken a step ...

Biologics are incredibly powerful and targeted. For these reasons, pharmaceutical companies have invested a lot of time and money over the past 20 years developing medications based on these ...

The market for gene therapies, CRISPR technologies, and biologics is expected to exceed $200 billion by 2025, as biotech firms develop personalized treatments and new therapies. Telemedicine ...

Returning for its 3rd year, Computational Drug Development for Biologics remains the only industry-centric meeting solely dedicated to exploring in-silico prediction, design, and modelling of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...